Chimeric antigen receptors modified T-cells for cancer therapy

Journal of the National Cancer Institute

Volumn 108, Issue 7, 2016, Pages

  Dai, Hanren ^a,b   Wang, Yao ^a,b   Lu, Xuechun ^b   Han, Weidong ^a,b  

^a School of Life Sciences   (United States)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CD19 ANTIGEN; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CELL HOMING; CYTOKINE RELEASE SYNDROME; DRUG SAFETY; GENE TRANSFER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T CELL CULTURE; T LYMPHOCYTE; ADVERSE EFFECTS; ANIMAL; CHIMERA; CLINICAL TRIAL (TOPIC); EVIDENCE BASED MEDICINE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; SIGNAL TRANSDUCTION; SYNDROME;

ANIMALS; ANTIGENS, CD19; CHIMERA; CLINICAL TRIALS AS TOPIC; CYTOKINES; EVIDENCE-BASED MEDICINE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SYNDROME; T-LYMPHOCYTES;

EID: 84979268324     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv439     Document Type: Review

References (162)

1. Soderqvist T, Stillwell C. A commotion in the blood: Life, death, and the immune system. J Hist Biol. 1999;32(1):205-215.
2. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666-675.
3. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550-4557.
4. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T-cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
5. Kalos M, Levine BL, Porter DL, et al. T-cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Science Transl Med. 2011;3(95):95ra73.
6. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
7. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T-cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
8. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T-cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
9. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T-cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
10. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T-cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517-528.
11. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T-cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.
12. Ahmed N, Brawley VS, Hegde M, et al. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T-cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015;33(15):1688-1696.
13. Eshhar Z, Waks T, Bendavid A, et al. Functional expression of chimeric receptor genes in human T-cells. J Immunol Methods. 2001;248(1-2):67-76.
14. Zhou G, Levitsky H. Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol. 2012;2012:124187.
15. Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res. 2007;67(5):1887-1892.
16. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):478-488.
17. Hombach A, Heuser C, Sircar R, et al. T-cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology. 1997;113(4):1163-1170.
18. Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T-cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Yexpressing tumors in mice. Proc Natl Acad Sci U S A. 2005;102(52):19051-19056.
19. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94(2):228-236.
20. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T-cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6056.
21. Abken H, Hombach A, Heuser C, et al. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T-cells with tumor specificity. Recent Results Cancer Res. 2001;158:249-264.
22. Wilkie S, Picco G, Foster J, et al. Retargeting of human T-cells to tumorassociated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180(7):4901-4909.
23. Chekmasova AA, Rao TD, Nikhamin Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T-cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010;16(14):3594-3606.
24. Hegde M, Corder A, Chow KK, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T-cells in glioblastoma. Mol Ther. 2013;21(11):2087-2101.
25. Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):1844-1852.
26. Tamada K, Geng D, Sakoda Y, et al. Redirecting gene-modified T-cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18(23):6436-6445.
27. Grada Z, Hegde M, Byrd T, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.
28. Moritz D, Groner B. A spacer region between the single chain antibodyand the CD3 zeta-chain domain of chimeric T-cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. 1995;2(8):539-546.
29. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T-cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 2010;17(10):1206-1213.
30. Kradin R, Kurnick J, Gifford J, et al. Adoptive immunotherapy with interleukin- 2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes. J Clin Immunol. 1989;9(5):378-385.
31. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028-7038.
32. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121(7):1165-1174.
33. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203-211.
34. Dustin ML, Depoil D. New insights into the T-cell synapse from single molecule techniques. Nat Rev Immunol. 2011;11(10):672-684.
35. Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T-cells. Cancer Res. 2004;64(24):9160-9166.
36. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T-cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-1464.
37. Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T-cells. Oncoimmunology. 2012;1(4):458-466.
38. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T-cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617-4627.
39. Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T-cells against B-cell malignancies. Hum Gene Ther. 2010;21(1):75-86.
40. Pule MA, Straathof KC, Dotti G, et al. A chimeric T-cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T-cells. Mol Ther. 2005;12(5):933-941.
41. Irving BA, Weiss A. The cytoplasmic domain of the T-cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64(5):891-901.
42. Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A. 1991;88(20):8905-8909.
43. Romeo C, Amiot M, Seed B. Sequence requirements for induction of cytolysis by the T-cell antigen/Fc receptor zeta chain. Cell. 1992;68(5):889-897.
44. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676-684.
45. Maher J, Brentjens RJ, Gunset G, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20(1):70-75.
46. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T-cells. Cancer Res. 2006;66(22):10995-11004.
47. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T-cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172(1):104-113.
48. Song DG, Ye Q, Poussin M, et al. CD27 costimulation augments the survival and antitumor activity of redirected human T-cells in vivo. Blood. 2012;119(3):696-706.
49. Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T-cells. Cancer Immunol Immunother. 2009;58(12):1991-2001.
50. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T-cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581-590.
51. Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/ Bcl-XL activation and CD8+ T-cell-mediated tumor eradication. Mol Ther. 2010;18(2):413-420.
52. Wang LX, Westwood JA, Moeller M, et al. Tumor ablation by gene-modified T-cells in the absence of autoimmunity. Cancer Res. 2010;70(23):9591-9598.
53. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T-cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106(9):3360-3365.
54. Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T-cells expressing chimeric antigen receptors can effectively Muster an antigen- independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697-5706.
55. Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T-cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133-4141.
56. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/ leukemia effects and safety. Leukemia. 2010;24(6):1160-1170.
57. Zhao Z, Condomines M, van der Stegen SJ, et al. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T-cells. Cancer Cell. 2015;28(4):415-428.
58. Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T-cells through constitutive CD40L expression. Mol Ther. 2015;23(4):769-778.
59. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101(4):1637-1644.
60. Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1(1):49-55.
61. Dupuy AJ, Akagi K, Largaespada DA, et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436(7048):221-226.
62. Huang X, Wilber AC, Bao L, et al. Stable gene transfer and expression in human primary T-cells by the Sleeping Beauty transposon system. Blood. 2006;107(2):483-491.
63. Jin Z, Maiti S, Huls H, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T-cells to express a chimeric antigen receptor. Gene Ther. 2011;18(9):849-856.
64. Maiti SN, Huls H, Singh H, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013;36(2):112-123.
65. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68(8):2961-2971.
66. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T-cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21(4):427-437.
67. Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009;32(8):826-836.
68. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther. 2006;13(1):151-159.
69. Birkholz K, Hombach A, Krug C, et al. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T-cells for use in the adoptive immunotherapy of cancer. Gene Ther. 2009;16(5):596-604.
70. Brown CE, Badie B, Barish ME, et al. Bioactivity and Safety of IL13Ralpha2- Redirected Chimeric Antigen Receptor CD8+ T-cells in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2015; In press.
71. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825-833.
72. Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol. 2012;24(5):598-608.
73. June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9(10):704-716.
74. Kustikova OS, Schiedlmeier B, Brugman MH, et al. Cell-intrinsic and vectorrelated properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol Ther. 2009;17(9):1537-1547.
75. Riviere I, Dunbar CE, Sadelain M. Hematopoietic stem cell engineering at a crossroads. Blood. 2012;119(5):1107-1116.
76. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T-cells to oncogene transformation. Blood. 2008;112(6):2278-2286.
77. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T-cells. Proc Natl Acad Sci U S A. 2006;103(5):1457-1462.
78. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
79. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T-cells. Sci Transl Med. 2012;4(132):132ra53.
80. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T-cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
81. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T-cells in lymphoma patients. J Clin Invest. 2011;121(5):1822-1826.
82. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/ CD19-specific chimeric antigen receptor redirected T-cells in humans. Biol Blood Marrow Transplant. 2010;16(9):1245-1256.
83. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689-702.
84. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T-cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540-549.
85. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19- targeted T-cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-4139.
86. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19- redirected virus-specific T-cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965-2973.
87. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233-5239.
88. Liu S, Riley J, Rosenberg S, et al. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J Immunother. 2006;29(3):284-293.
89. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T-cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480-490.
90. Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T-cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750-3759.
91. Davila ML, Brentjens R, Wang X, et al. How do CARs work': Early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012;1(9):1577-1583.
92. Maus MV, Grupp SA, Porter DL, et al. Antibody-modified T-cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123(17):2625-2635.
93. Li YS, Wasserman R, Hayakawa K, et al. Identification of the earliest B lineage stage in mouse bone marrow. Immunity. 1996;5(6):527-535.
94. Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med. 1993;178(3):951-960.
95. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T-cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13(18 Pt 1):5426-5435.
96. Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-4023.
97. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T-cells. Blood. 2012;119(12):2709-2720.
98. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T-cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.
99. Dai H, Zhang W, Li X, et al. Tolerance and efficacy of autologous or donorderived T-cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. OncoImmunology. 2015;4(11):e1027469.
100. Wang Y, Zhang WY, Han QW, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T-cells. Clin Immunol. 2014;155(2):160-175.
101. Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119(17):3940-3950.
102. Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T-cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122-2129.
103. Wang QS, Wang Y, Lv HY, et al. Treatment of CD33-directed chimeric antigen receptor-modified T-cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther. 2015;23(1):184-191.
104. Garfall AL, Maus MV, Hwang WT, et al. Chimeric Antigen Receptor T-cells against CD19 for Multiple Myeloma. N Engl J Med. 2015;373(11):1040-1047.
105. Burga RA, Thorn M, Point GR, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64(7):817-829.
106. Katz SC, Burga RA, McCormack E, et al. Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases. Clin Cancer Res. 2015;21(14):3149-3159.
107. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
108. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T-cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904-912.
109. Lamers CH, Langeveld SC, Groot-van Ruijven CM, et al. Gene-modified T-cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother. 2007;56(12):1875-1883.
110. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20-e22.
111. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T-cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106-6115.
112. Hosing C, Kebriaei P, Wierda W, et al. CARs in chronic lymphocytic leukemia - ready to drive. Curr Hematol Malig Rep. 2013;8(1):60-70.
113. Brentjens RJ, Curran KJ. Novel cellular therapies for leukemia: CAR-modified T-cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program. 2012;2012:143-151.
114. Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T-cell-engaging therapies. Cancer J. 2014;20(2):119-122.
115. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T-cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053-9061.
116. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489-500.
117. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673-1683.
118. Maus MV, Haas AR, Beatty GL, et al. T-cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26-31.
119. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood. 2003;101(4):1290-1298.
120. Berger C, Flowers ME, Warren EH, et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T-cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107(6):2294-2302.
121. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708-4715.
122. Song DG, Ye Q, Poussin M, et al. A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget. 2015;6(25):21533-21546.
123. Wang X, Chang WC, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118(5):1255-1263.
124. Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T-cells. Nat Biotechnol. 2013;31(1):71-75.
125. Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.
126. Caruso HG, Hurton LV, Najjar A, et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 2015;75(17):3505-3518.
127. Liu X, Jiang S, Fang C, et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T-cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 2015;75(17):3596-3607.
128. Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113(25):6392-6402.
129. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367(2):135-145.
130. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T-cells in myeloma and melanoma. Blood. 2013;122(6):863-871.
131. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLAA1- presented peptide as a cross-reactive target for engineered MAGE A3-directed T-cells. Sci Transl Med. 2013;5(197):197ra103.
132. Craddock JA, Lu A, Bear A, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T-cells by expression of the chemokine receptor CCR2b. J Immunother. 2010;33(8):780-788.
133. Chinnasamy D, Yu Z, Kerkar SP, et al. Local delivery of interleukin-12 using T-cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res. 2012;18(6):1672-1683.
134. Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat Med. 2015;21(5):524-529.
135. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T-cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28-36.
136. Ganss R, Ryschich E, Klar E, et al. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002;62(5):1462-1470.
137. Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CD4(+)FoxP3(+) regulatory T-cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012;119(24):5688-5696.
138. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T-cells. J Exp Med. 2005;202(7):907-912.
139. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T-cells derived from central memory cells establishes persistent T-cell memory in primates. J Clin Invest. 2008;118(1):294-305.
140. Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T-cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A. 2009;106(41):17469-17474.
141. Wang X, Naranjo A, Brown CE, et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T-cells manufactured at clinical scale. J Immunother. 2012;35(9):689-701.
142. Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cellderived immunocompetence reveals stemness of CD8(+) central memory T-cells. Immunity. 2014;41(1):116-126.
143. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T-cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15(7):808-813.
144. Pegram HJ, Purdon TJ, van Leeuwen DG, et al. IL-12-secreting CD19-targeted cord blood-derived T-cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia. 2015;29(2):415-422.
145. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38(1):13-25.
146. Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimericantigen- receptor and eliminate expression of endogenous TCR. Blood. 2012;119(24):5697-5705.
147. Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res. 2015;75(18):3853-3864.
148. Foster AE, Dotti G, Lu A, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008;31(5):500-505.
149. Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T-cells and tumor cells. Cancer Res. 2011;71(6):2066-2076.
150. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T-cells. J Immunol. 2013;190(5):2455-2463.
151. Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T-cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol. 2009;183(11):6939-6947.
152. Condomines M, Arnason J, Benjamin R, et al. Tumor-Targeted Human T-cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS One. 2015;10(6):e0130518.
153. Dotti G, Savoldo B, Pule M, et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood. 2005;105(12):4677-4684.
154. Eaton D, Gilham DE, O'Neill A, et al. Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. 2002;9(8):527-535.
155. Chang ZL, Silver PA, Chen YY. Identification and selective expansion of functionally superior T-cells expressing chimeric antigen receptors. J Transl Med. 2015;13:161.
156. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10):e26286.
157. John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T-cells. Clin Cancer Res. 2013;19(20):5636-5646.
158. Prosser ME, Brown CE, Shami AF, et al. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T-cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51(3-4):263-272.
159. Ninomiya S, Narala N, Huye L, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T-cells and is downregulated by lymphodepleting drugs. Blood. 2015;125(25):3905-3916.
160. Cheadle EJ, Gornall H, Baldan V, et al. CAR T-cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014;257(1):91-106.
161. Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T-cells. Blood. 2008;112(6):2261-2271.
162. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T-cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.